Veru (VERU)
(Delayed Data from NSDQ)
$0.90 USD
-0.02 (-1.80%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $0.91 +0.01 (0.92%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Veru Inc. [VERU]
Reports for Purchase
Showing records 21 - 40 ( 94 total )
Company: Veru Inc.
Industry: Medical - Products
Sabizabulin Granted Expedited Regulatory Pathway in Australia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Company: Veru Inc.
Industry: Medical - Products
EMA Initiates Review of Sabizabulin for COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
UK Regulatory Agency Supports Expedited Review of COVID Drug; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Sabizabulin Phase 3 COVID-19 Trial Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 1b/2 Prostate Cancer Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
EUA Application Submitted For Hospitalized COVID-19 Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Company: Veru Inc.
Industry: Medical - Products
FDA Supports EUA Submission of Sabizabulin for COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 2 COVID-19 Treatment Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Sabizabulin Reduces COVID-19 Deaths by 55% in Hospitals
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Updated Phase 1b/2 Prostate Cancer Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
COVID-19 Trial Continues After Conditional Power Analysis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Company: Veru Inc.
Industry: Medical - Products
Eli Lilly Collaboration Inked for Phase 3 Breast Cancer Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Sabizabulin Obtains Fast Track Designation for COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fast Track Designation Granted for Enobosarm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
FDA Approves ENTADFI for Benign Prostatic Hyperplasia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
FY21 Financial Results Reported; Potential ENTADFI Approval Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Enobosarm Phase 3 Breast Cancer Trial Starts Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y